Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 7, 2004, Pages 1118-1126

  Morel, O ^a,b   Hugel, B ^b,c   Jesel, L ^a   Mallat, Z ^c   Lanza, F ^c   Douchet, M P ^a   Zupan, M ^a   Chauvin, M ^a   Cazenave, J P ^c   Tedgui, A ^c   Freyssinet, J M ^b,d   Toti, Florence ^b,d,e  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSERM   (France)

^d Dept Environ Med Natl Inst Publ HIth   (Norway)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Abciximab; Acute coronary syndrome; Eptifibatide; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; GLYCOPROTEIN V; HEPARIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PROCOAGULANT; THROMBIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DISEASE MARKER; ENZYME ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LEUKOCYTE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; ST SEGMENT; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTICLE SIZE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOLUBILITY; THROMBOPHILIA;

EID: 19944433984     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00805.x     Document Type: Article

References (50)

1. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
2. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101 41-3.
3. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, Freyssinet JM. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99: 1546-54.
4. Sabatier V, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99: 3962-70.
5. Vidal C, Spaulding C, Picard F, Schaison F, Melle J, Weber S, Fontenay-Roupie M. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001; 86: 784-90.
6. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-70.
7. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88: 998-1003.
8. Muller I, Klocke A, Alex M, Kotsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factors initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-8.
9. Biro E, Sturk-Maquelin KN, Vogel GMT, Meuleman DG, Smit MJ, Hack CE, Sturk A, Nieuwland R. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-8.
10. Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, Ferguson JJ 3rd, Willerson JT, Weisman HF, Topol EJ. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001; 37: 2059-65.
11. Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, Lopez-Sendon JL, Meyer J, Van de Werf F, ASSENT-3 Investigators. Outcome of urgent and elective percutaneous coronary interventions after pharmacological reperfusion with tenecteplase combined with unfractionned heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003; 42: 1178-85.
12. ASSENT-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionned heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
13. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996; 98: 863-74.
14. Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S, Ruggeri ZM. Different effects of various anti-GPIIb-IIIa agents on shear induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-30.
15. Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP, Lip GY. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis - the influence of aspirin and cigarette smoking. Thromb Haemost 2001; 86: 777-83.
16. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99: 2794-800.
17. Ardissino D, Merlini PA, Bauer KA, Bramucci E, Ferrario M, Coppola R, Fetiveau R, Lucreziotti S, Rosenberg RD, Mannucci PM. Thrombogenic potential of human coronary atherosclerotic plaques. Blood 2001; 98: 2726-9.
18. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37.
19. Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM, Scrobohaci ML. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
20. Morel O, Jesel L, Hugel B, Douchet MP, Zupan M, Chauvin M, Freyssinet JM, Toti F. Protective effects of vitamin C on endothelium damage and platelet activation in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003; 1: 171-7.
21. Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999; 274: 23111-8.
22. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-87.
23. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-52.
24. Kopp CW, Steiner S, Nasel C, Seidinger D, Mlekusch I, Lang W, Bartok A, Ahmadi R, Minar E. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke 2003; 34: 2560-7.
25. Fujimi S, Ogura H, Tanaka H, Koh T, Hosotsubo H, Nakamori Y, Kuwagata Y, Shimazu T, Sugimoto H. Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 2002; 52: 443-8.
26. Mesri M, Altieri DC. Endothelial cell activation by leukocyte micro-particles. J Immunol 1998; 161: 4382-7.
27. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-89.
28. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticles P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
29. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, Shacter E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003; 4: 87-91.
30. Manten A, de Winter RJ, Minnema MC, ten Cate H, Lijmer JG, Adams R, Peters RJ, van Deventer SJ. Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res 1998; 40 389-95.
31. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993; 268: 14586-9.
32. Lages B, Weiss HJ. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb-IIIa inhibitors than by peptide and peptidomimetic inhibitors. Br J Haematol 2001; 113: 65-71.
33. Ilverskero S, Lassila R. Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets. J Thromb Haemost 2003; 1: 805-13.
34. Haga JH, Slack SM, Jennings LK. Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of alpha IIb beta3 antagonists. J Cardiovasc Pharmacol 2003; 41: 363-71.
35. Furman MI, Krueger LA, Frelinger AL 3rd, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
36. Craft JA, Marsh NA. Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty. Blood Coagul Fibrinolysis 2003; 14: 719-28.
37. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104 163-7.
38. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998; 102: 136-44.
39. Schwarz M, Nordt T, Bode C, Peter K. The GPIIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CDIIb/CD18, alphaMbeta2). Thromb Res 2002; 107 121-8.
40. Yeh CH, Peng HC, Huang TF. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood 1998; 92: 3268-76.
41. Aymong ED, Curtis MJ, Youssef M, Graham MM, Shewchuk L, Leschuk W, Anderson TJ. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002; 105: 2981-5.
42. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37: 1323-8.
43. Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM. IIb's are not IIb's. Am J Cardiol 2000; 85: 23C-31C.
44. Goto S, Eto K, Ikeda Y, Handa S. Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear. Lancet 1999; 353: 809.
45. Chang WC, Harrington RA, Simoons ML, Califf RM, Lincoff AM, Armstrong PW. Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. Eur Heart J 2002; 23: 1102-11.
46. Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 2002; 87: 1020-5.
47. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-78.
48. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-8.
49. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107: 1123-8.
50. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM. Multi-year follow-up of abciximab therapy in three randomized, placebo- controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113: 1-6.